The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
GLP-1 medications like Ozempic and Mounjaro aren't just shedding pounds—they're slimming down grocery bills, restaurant tabs, and alcohol sales while boosting fitness and fashion spending. With 2.5 million UK users and rising, businesses are adapting fast. Learn the science behind these shifts and how to navigate them effectively.
The chilling film 'Saccharine' imagines a diet pill worse than Ozempic—made from human ashes. But what does it reveal about real GLP-1 weight loss drugs? This guide dives into the science, psychological pitfalls, and evidence-based tips for safe use.
At 400lbs, Devyn McGuire hit rock bottom, but two simple changes—walking and calorie control—sparked a 200lb transformation without Ozempic or Wegovy. His story proves natural methods can rival medications when backed by science and consistency. Learn the strategies, mechanisms, and mindset for your own success.
The NHS has approved a triple-strength 7.2mg Wegovy dose, promising greater weight loss for those plateauing on standard semaglutide. One user's story highlights the frustration of switching from Mounjaro due to costs, sparking debate on higher GLP-1 doses. Discover the science, safety, and what it means for metabolic health.
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
GLP-1 injections like Ozempic, Wegovy, and Mounjaro have exploded from niche diabetes therapies to cultural icons in weight management. While offering profound metabolic benefits, their rapid mainstreaming raises questions about proper use, side effects, and societal pressures. This guide unpacks the science, real-world stories, and future implications.
GLP-1 medications like Zepbound have transformed lives, helping patients lose significant weight amid personal challenges. But rapid results come with risks like gallstones and muscle loss. This guide blends real stories with clinical insights for informed decisions.
Ozempic and Wegovy have transformed weight management, but high costs limit access. A Spanish company is now manufacturing generic semaglutide, poised to slash prices as patents expire. This guide explores the implications for patients seeking affordable GLP-1 therapy.
Demand for GLP-1 weight loss medications is soaring, but the shift to easier-to-fake oral pills spells trouble. Counterfeit versions pose serious health risks, from incorrect dosing to contamination. This guide explains the threats and equips you with strategies to stay safe.
